Remedial care is a central component of symptomatic and palliative treatment for amyotrophic lateral sclerosis (ALS). The subjective experience of therapies including physiotherapy, occupational therapy and speech therapy is largely unknown.
By surveying recommendations for physiotherapy, occupational therapy and speech therapy, Ambulanzpartner examined the patient perspective on their treatment.
We surveyed 256 people with ALS between 07/2014 and 08/2017 about their treatment. The Net Promotor Score(NPS) was used to record the probability of recommending the therapy online (“How likely is it that you would recommend physiotherapy (occupational therapy, speech therapy) to a friend or colleague (m/f) who has ALS?”). The answers are given on a nominal scale between 0 (absolutely unlikely to recommend) and 10 (highly likely to recommend) scale points. The evaluation was carried out according to the following system:
Likely recommendation: 10 or 9 points
Indifferent recommendation: 8 or 7 points
Unlikely recommendation: 6 to 0 points
The NPS was collected digitally via our outpatient partner care portal and the evaluation of the data shows that the probability of recommendation of all forms of therapeutic care is predominantly high to very high (Fig. 1).
| |
Speech therapy has the highest recommendation rate. However, special speech therapy interventions are less clearly recommended (Fig. 4). Special physiotherapy interventions vary significantly in some cases (Fig. 2). In occupational therapy, on the other hand, there is no relevant difference in special therapy procedures (Fig. 3).
| |
The study shows that the satisfaction of ALS patients with speech therapy, physiotherapy and occupational therapy is predominantly high. Against the background of the progressive nature of ALS and the conservative objective of the therapies, the high recommendation rate is of particular relevance. The results of our study support the provision of remedies for people with ALS, which is largely based on the subjective experience of patients.
The study was presented and discussed at the Congress of the German Neurological Society in Leipzig on September 22, 2017.
On December 4, 2025, the ALS app will be presented at the"ALS App Europe Initiative…
Following our last newsletter on the introduction of the OPM classification in the ALS app,…
You can now submit your e-prescription with your health card via the ALS app at…
We are pleased to introduce an important new feature in the ALS app today: The…
The THC:CBD patient survey is a systematic survey of 130 patients with amyotrophic lateral sclerosis…
We are pleased to inform you that we have completely revised our medication module. With…